Dr Carole Guillonneau, of the Center of Research in Transplantation and Immunology (CRTI) in Nantes, France has presented proof-of-concept preclinical data generated by TxCell and CRTI at the annual meeting of the Federation of Clinical Immunology Societies (FOCIS 2018) in San Francisco, USA in June.
Entitled ‘Cell therapy with engineered HLA-A2 specific CAR-CD8+ Tregs to avoid transplant rejection’, the presentation is the first to deliver data obtained by TxCell and CRTI with proprietary CD8+ CAR-Tregs (HLA-A2 CAR-Tregs) in relevant animal models of graft-versus-host disease and skin graft.
In these models, CD8+ CAR-Tregs showed a significant impact on mice survival and delay of skin graft rejection vs control. It was also demonstrated that the transduction of a CAR into a CD8+ Treg cell had no impact on the cell phenotype nor on the Treg function, notably its suppressive activity.
“These new proof-of-concept data demonstrate the progress TxCell and CRTI have made since the start of their collaboration only 12 months ago,” said François Meyer, PhD, Chairman of the Board and Head of Research at TxCell. “TxCell now has three CAR-Treg platforms supported by encouraging data. This makes us a clear leader in this emerging field. We expect to start soon the development in humans of the first of these platforms, the CD4+ CAR-Treg platform, with TX200, our lead CAR-Treg programme targeting HLA-A2 for the prevention of chronic rejection after organ transplantation. TxCell will continue in parallel to invest in its earlier stage CD8+ Treg and Tr1 platforms. This will give the best chance to TxCell to select the most appropriate approach for patients in areas of significant unmet medical need.”
- Sangamo finalises TxCell acquisition
- TxCell terminates OCABSA financing programme following majority stake acquisition by Sangamo
- TxCell exercises in-licence option to University of British Columbia’s CAR-Treg programme IP rights
- TxCell appoints Lonza as CAR-Treg cellular product manufacturer
- TxCell appoints Lentigen as manufacturer of lentiviral vector for transplant rejection therapy
- TxCell and Inserm develop new CAR-Tregs in transplantation and multiple sclerosis
Latest from Tom Mulligan
- EVENT PREVIEW: CPhI North America opens next week!
- NEW BUSINESS: SK biotek and AMPAC Fine Chemicals have ambitious CDMO plans
- NEW TECHNOLOGY: Polyplus-transfection develops GMP-grade therapeutic virus reagent
- Mogrify raises $3.7 million seed funding to support direct cellular conversion for cell therapy
- Owlstone Medical partners with Shanghai Renji Hospital to pioneer Breath Biopsy lung cancer trial
- Chemspace and LabNetwork collaborate to extend access to chemical databases
- TECHNOLOGY UPDATE: Catalent invests over $27 million to commercialise next-generation ODT Zydis Ultra
- SGS reports successful Phase 2 results for novel influenza vaccine, validating its H3N2 A/Belgium challenge agent
- NEW TECHNOLOGY: Horizon Discovery and Rutgers University develop new gene editing approach: ‘base editing’
- EVENT REVIEW: Busy sessions at BIO-Europe Spring!